Madrigal (MDGL) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
180.1M
Gross Profit
173.9M
96.54%
Operating Income
-497.9M
-276.39%
Net Income
-465.9M
-258.64%
EPS (Diluted)
-$21.90
Balance Sheet Metrics
Total Assets
1.0B
Total Liabilities
287.9M
Shareholders Equity
754.4M
Debt to Equity
0.38
Cash Flow Metrics
Operating Cash Flow
-455.6M
Free Cash Flow
-462.0M
Revenue & Profitability Trend
Madrigal Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 180.1M | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | 6.2M | - | - | - | - |
| Gross Profit | 173.9M | - | - | - | - |
| Operating Expenses | 671.8M | 380.5M | 293.6M | 242.5M | 206.7M |
| Operating Income | -497.9M | -380.5M | -293.6M | -242.5M | -206.7M |
| Pre-tax Income | -465.9M | -373.6M | -295.4M | -241.8M | -202.2M |
| Income Tax | - | - | - | - | - |
| Net Income | -465.9M | -373.6M | -295.4M | -241.8M | -202.2M |
| EPS (Diluted) | -$21.90 | -$19.99 | -$17.23 | -$14.63 | -$13.09 |
Income Statement Trend
Madrigal Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.0B | 637.3M | 361.4M | 271.7M | 285.2M |
| Non-Current Assets | 9.3M | 3.3M | 1.2M | 1.6M | 1.8M |
| Total Assets | 1.0B | 640.5M | 362.6M | 273.3M | 287.0M |
| Liabilities | |||||
| Current Liabilities | 169.3M | 118.5M | 115.9M | 76.8M | 46.6M |
| Non-Current Liabilities | 118.6M | 116.7M | 49.3M | 387.0K | 468.0K |
| Total Liabilities | 287.9M | 235.2M | 165.2M | 77.2M | 47.0M |
| Equity | |||||
| Total Shareholders Equity | 754.4M | 405.3M | 197.4M | 196.1M | 240.0M |
Balance Sheet Composition
Madrigal Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -465.9M | -373.6M | -295.4M | -241.8M | -202.2M |
| Operating Cash Flow | -455.6M | -316.7M | -260.0M | -194.2M | -181.2M |
| Investing Activities | |||||
| Capital Expenditures | -1.5M | -1.5M | -217.0K | -209.0K | -334.0K |
| Investing Cash Flow | -269.4M | -502.5M | 206.7M | -5.1M | 159.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 397.5M | 324.8M | 304.5M | 170.2M | 4.4M |
| Free Cash Flow | -462.0M | -325.7M | -225.1M | -184.1M | -157.9M |
Cash Flow Trend
Madrigal Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-13.01
Forward P/E
-20.27
Price to Book
8.84
Price to Sales
19.80
PEG Ratio
-20.27
Profitability Ratios
Profit Margin
-123.38%
Operating Margin
-57.79%
Return on Equity
-50.16%
Return on Assets
-25.56%
Financial Health
Current Ratio
5.91
Debt to Equity
16.85
Beta
-1.08
Per Share Data
EPS (TTM)
-$17.84
Book Value per Share
$32.03
Revenue per Share
$14.56
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| mdgl | 6.3B | -13.01 | 8.84 | -50.16% | -123.38% | 16.85 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.